New safety and efficacy data of the ongoing phase I/II study (ASET Study) with an allogeneic tumor vaccine and adjuvant in patients with metastatic renal cell carcinoma.
Viktor Grünwald(Deutsche Schmerzgesellschaft), Burghardt Wittig, Stefan Hauser(German Center for Neurodegenerative Diseases), Marina Tschaika(Bristol-Myers Squibb (United States)), Ekaterina Weith(Mologen (Germany)), Ingo GH Schmidt-Wolf(University Hospital Bonn), Manuel Schmidt(Mologen (Germany)), Steffen Weikert(St. Hedwig-Krankenhaus), Matthias Schroff(Mologen (Germany))
Cited by 1
Related Papers
The Epidemiology of Renal Cell Carcinoma
|European Urology|2011|1k
Nivolumab versus standard, single-agent therapy of investigator's choice in recurrent or metastatic squamous cell carcinoma of the head and neck (CheckMate 141): health-related quality-of-life results from a randomised, phase 3 trial
|The Lancet Oncology|2017|431
Association of inflammatory biomarkers with clinical outcomes in nivolumab-treated patients with advanced hepatocellular carcinoma
|Journal of Hepatology|2020|421
Phase III Trial of Ipilimumab Combined With Paclitaxel and Carboplatin in Advanced Squamous Non–Small-Cell Lung Cancer
|Journal of Clinical Oncology|2017|380